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Background-—Prior studies have reported conﬂicting ﬁndings with regard to the association of biomarkers in the prediction of
incident type 2 diabetes. We evaluated 12 biomarkers as possible diabetes predictors in the Framingham Heart Study.
Methods and Results-—Biomarkers representing inﬂammation (C-reactive protein, interleukin-6, monocyte chemoattractant
protein-1, tumor necrosis factor receptor 2, osteoprotegerin, and ﬁbrinogen), endothelial dysfunction (intercellular adhesion
molecule-1), vascular damage (CD40-ligand, P-selectin, and lipoprotein-associated phospholipase A2 mass and activity), and
oxidative stress (urinary isoprostanes) were measured in participants without diabetes attending the Offspring seventh (n=2499) or
multiethnic Omni second (n=189) examination (1998–2001). Biomarkers were loge transformed and standardized. Multivariable
logistic regression tested each biomarker in association with incident diabetes at a follow-up examination (the Offspring eighth and
Omni third examination; mean 6.6 years later), with adjustment for age, sex, cohort, body mass index, fasting glucose, systolic
blood pressure, high-density lipoprotein cholesterol, triglycerides, and smoking. C statistics were evaluated with and without
inﬂammatory markers. In 2638 participants (56% women, mean age 59 years), 162 (6.1%) developed type 2 diabetes. All
biomarkers, excluding osteoprotegerin, were associated with the outcome with adjustment for age, sex, and cohort; however, none
remained signiﬁcant after multivariable adjustment (all P>0.05). The c statistic from the model including only clinical covariates
(0.89) did not statistically signiﬁcantly improve after addition of biomarkers (all P>0.10).
Conclusions-—Biomarkers representing different inﬂammatory pathways are associated with incident diabetes but do not remain
statistically signiﬁcant after adjustment for established clinical covariates. Inﬂammatory biomarkers might not be an effective
resource to predict type 2 diabetes in community-based samples. (J Am Heart Assoc. 2012;1:e000869 doi: 10.1161/
JAHA.112.000869)
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A
ccording to the Centers for Disease Control and
Prevention, 25.6 million people were affected by diabe-
tes in the United States in 2010, representing a 1.9-million–
person increase over the previous year.
2 The risk for death
among people with diabetes is about twice that of people of
similar age without diabetes, and the estimated costs for
diabetes in the United States in 2007 were $174 billion, with
$116 and $58 billion as direct and indirect medical costs,
respectively.
3
The importance of identifying individuals at high risk for the
development of incident diabetes is supported by the results
of the Diabetes Prevention Program, which showed that type
2 diabetes can be either prevented or delayed through
lifestyle modiﬁcations and medications.
4,5 Several different
types of risk scores that incorporate clinical and nutritional
variables have been developed around the world in an attempt
to identify individuals at high risk for new-onset type 2
diabetes.
6–8
The idea of a possible inﬂammatory etiology of diabetes
originated >100 years ago, when high doses of sodium
salicylate were effective in diminishing glycosuria among
patients with the milder form of diabetes, most likely type 2
diabetes.
9 This led to great interest in the concept that
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ORIGINAL RESEARCHbiomarkersofinﬂammationcouldimprovetheabilitytoidentify
individuals at risk for development of diabetes. However,
previousstudiesevaluatingtheroleofinﬂammatorybiomarkers
as possible predictors for the onset of type 2 diabetes in
addition to the established clinical covariates reported con-
ﬂicting ﬁndings.
10–20 In addition, the majority of the studies
demonstrating a valuable role for inﬂammatory biomarker(s) as
predictorsfortheonsetoftype2diabeteswerebasedoncase–
control studies, which not only lack the ability to establish
temporality but also do not allow for a population-based
assessment of risk-prediction metrics with and without the
novel biomarker of interest. Thus, the purpose of the present
study was to examine in a prospective cohort study, the
Framingham Heart Study, whether inﬂammatory biomarkers
improved the prediction of incident type 2 diabetes after
adjustment for clinical covariates. We chose 12 biomarkers
representingmultipleinﬂammatorypathways,includinginﬂam-
mation (C-reactive protein [CRP], interleukin-6, monocyte
chemoattractant protein-1, tumor necrosis factor receptor 2,
osteoprotegerin,andﬁbrinogen),endothelialdysfunction(inter-
cellular adhesion molecule), vascular damage (CD40-ligand, P-
selectin, and lipoprotein-associated phospholipase A2), and
oxidative stress (urinary isoprostanes).
Methods
The present study was conducted in the Framingham Heart
Study, a community-based, observational epidemiological
cohort. The design and selection criteria of the Framingham
Offspring study have been described.
21 The Omni cohort,
started in 1994, consisted of 506 men and women of
African American, Hispanic, Asian, Indian, Paciﬁc Islander,
and Native American origins, who were residents of
Framingham, MA, and surrounding towns at the time of
enrollment. The baseline assessment for the present study
involved Offspring participants at the seventh examination
cycle (n=3539) and Omni participants at the second
examination cycle (n=405). Participants were assessed for
new-onset diabetes at the eighth follow-up examination for
the Offspring and the third follow-up examination for the
Omni participants. Participant exclusion criteria were as
follows: prevalent type 2 diabetes at baseline (Offspring,
n=366; Omni, n=53); off-site baseline examination (Offspring,
n=205; Omni, n=2); missing baseline plasma glucose level
(Offspring, n=3; Omni, n=69); incomplete information at
baseline about baseline type 2 diabetes status, biomarkers,
and clinical covariates (Offspring, n=17; Omni, n=2); failure
to attend the subsequent examination (Offspring, n=416;
Omni, n=78); and missing glucose data (Offspring, n=19;
Omni, n=2) or incomplete diabetes status (Offspring,
n=64; Omni, n=10) at the subsequent examination. Thus, a
total of 2638 participants were included in the study
(Offspring, n=2449; Omni, n=189). The study protocol was
reviewed and approved by the Institutional Review Board of
Boston University Medical Center. All participants gave
written informed consent.
Measurement of Inﬂammatory Biomarkers
at Baseline Exam
Fasting samples were obtained at the seventh examination
cycle for the Offspring participants and at the second
examination cycle for the Omni participants, who had rested
for 5 to 10 minutes in a supine position. Samples were stored
and frozen at 80°C until testing. Serum CRP was measured
with a high-sensitivity assay (Dade Behring BN100 nephe-
lometer, Deerﬁeld, IL). Commercially available ELISA methods
(R&D Systems, Minneapolis, MN) were used to measure the
serum concentrations of interleukin-6, intercellular adhesion
molecule-1, and monocyte chemoattractant protein-1 and the
plasma concentrations of CD40 ligand, osteoprotegerin,
P-selectin, and tumor necrosis factor receptor 2. Plasma
ﬁbrinogen was measured by the Clauss method. Lipoprotein-
associated phospholipase A2 mass and activity were measured
by DiaDexus, Inc, San Francisco, CA. Urinary isoprostanes,
8-Epi-PGF2a, were indexed to urinary creatinine (ACE Com-
petitive EIA – Cayman Chemical). All intra-assay coefﬁcients
of variation were ≤9.1%.
Incident Type 2 Diabetes
New cases of type 2 diabetes were ascertained at the follow-
up examination corresponding to examination cycle 8 for the
Offspring and examination cycle 3 for the Omni (mean time of
follow-up after baseline, 6.6 years; minimum 3.7, maximum
8.7 years). Type 2 diabetes was deﬁned by a fasting glucose
level ≥126 mg/dL or the use of insulin or oral hypoglycemic
medications at the time of follow-up.
Covariate Assessment
The covariates were deﬁned at baseline examination through
assessment of questionnaires, physicals, and laboratory
tests. Current smoking status was classiﬁed by self-report
of cigarette smoking during the year before examination.
Blood pressure was measured twice at rest in a seated
position by a physician using a mercury column sphygmo-
manometer, and measurements were averaged. Hypertension
was deﬁned as systolic blood pressure ≥140 mm Hg,
diastolic blood pressure ≥90 mm Hg, or the use of anti-
hypertensive medications. Body mass index was deﬁned as
the individual’s body weight divided by height squared. Lipid
proﬁles, plasma glucose, and insulin levels were measured
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assays. Impaired fasting glucose was deﬁned as a fasting
glucose level >100 mg/dL but <126 mg/dL. Aspirin use was
deﬁned as ≥3 doses per week.
Statistical Analyses
Discrete variables are presented as counts and percentages,
and continuous variables as means and standard deviations.
The inﬂammatory markers’ concentrations had skewed
distributions and were natural log transformed. For compa-
rable interpretations, the log biomarker concentrations were
standardized (mean 0 and standard deviation 1). We
estimated Pearson correlations among inﬂammatory biomar-
kers as well as between inﬂammatory biomarkers and clinical
covariates.
We performed multivariable logistic regression with inci-
dent type 2 diabetes as the outcome. We evaluated the
association of each individual inﬂammatory biomarker with
the outcome, adjusting ﬁrst for age, sex, and cohort (model
1). Then we added the following clinical covariates to model 1:
body mass index, fasting glucose, systolic blood pressure,
high-density lipoprotein cholesterol, triglycerides, and smok-
ing (model 2). We estimated and compared the area under the
curve between the baseline model including only clinical
covariates and model 2 for each inﬂammatory biomarker.
Differences in the c statistics were tested by the DeLong
nonparametric method. The odds ratio is interpreted as the
associated odds of developing diabetes per 1 standard
deviation of the log biomarker level.
Secondary Analyses
A test for effect modiﬁcation by sex was performed for the
inﬂammatory biomarkers with covariates from model 2. The
available literature evaluating the role of CRP as a predictor
for type 2 diabetes examined this association by comparing
the upper quartiles with the lowest one.
10–20 We evaluated
the association between CRP and incident type 2 diabetes by
performing a nonparametric analysis with splines, followed by
an analysis of the association between sex-speciﬁc quartiles
of CRP and the new onset of type 2 diabetes, with the use of
model 1 and model 2.
For all analyses, we used SAS version 8.1 (SAS Institute,
Cary, NC). For effect modiﬁcation analyses, we established a
signiﬁcance level of P<0.01; for all other analyses we
considered P<0.05 to be statistically signiﬁcant.
Results
Table 1 shows the participants’ clinical characteristics at
baseline, as well as by presence or absence of diabetes at the
follow-up examination. There were 2638 participants (mean
age 59±9 years, 56% women); most were white (93%). At
baseline 890 (34%) individuals had impaired fasting glucose.
At least 40% of the participants were receiving hypertension
medications, lipid treatments, or aspirin at the time of follow-
up. New-onset type 2 diabetes was detected in 162 partic-
ipants at the follow-up examination (6.1% incidence). Among
the new cases of type 2 diabetes, 121 were noted to have
impaired fasting glucose at baseline. Those who developed
diabetes in follow-up were more likely to be men and more
likely to have been obese and to have had higher mean age
and triglyceride levels, lower mean high-density lipoprotein
concentrations, and higher prevalence of impaired fasting
glucose, hypertension, or dyslipidemia at baseline. With
regard to the inﬂammatory biomarkers, participants with
incident diabetes had higher baseline levels of CRP, ﬁbrino-
gen, interleukin-6, urinary isoprostanes, lipoprotein-associ-
ated phospholipase A2 mass, monocyte chemoattractant
Table 1. Participants’ Characteristics at Baseline and
According to Diabetes Status at Follow-Up
Total
(n=2638)
Diabetes
(n=162)
No Diabetes
(n=2476)
Age, y 59±96 2 ±95 9 ±9
Women, % 1479 (56) 69 (43) 1410 (57)
Race, n (%)
White 2449 (93) 144 (89) 2305 (93)
African American 81 (3) 7 (4) 74 (3)
Hispanic 51 (2) 5 (3) 46 (2)
Asian 57 (2) 6 (4) 51 (2)
Omni, n (%) 189 (7) 18 (11) 171 (7)
Body mass
index, kg/m
2
27.7±5.1 31.5±5.6 27.5±4.9
Glucose, mg/dL 97±10 109±11 96±9
Triglycerides, mg/dL 129±80 180±136 125±73
High-density lipoprotein
cholesterol, mg/dL
55±17 46±14 56±17
Systolic blood
pressure, mm Hg
125±18 135±18 124±18
Impaired fasting
glucose, n (%)
890 (34) 121 (75) 769 (31)
Hypertension, n (%) 1018 (39) 110 (68) 908 (37)
Hypertension
treatment, n (%)
712 (27) 78 (48) 634 (26)
Lipid treatment, n (%) 444 (17) 48 (30) 396 (16)
Smoking, n (%) 306 (12) 18 (11) 288 (12)
Aspirin use, n (%) 725 (27) 62 (38) 663 (27)
Continuous variables are expressed as mean ± standard deviation.
Dichotomous variables are expressed as n (%).
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(Table 2). The reasons for exclusion and the clinical charac-
teristics of those who did and did not attend the follow-up
examination are presented in Tables 3 and 4. Participants not
returning for follow-up were more likely to be ethnic or racial
minorities, to have older mean ages, to have cardiovascular
disease, and to have died in the interim.
Relation of Individual Biomarkers With Incident
Type 2 Diabetes
Adjusting for age, sex, and cohort, we found an association
between the following 7 biomarkers and type 2 diabetes
(all P<0.02): CRP, ﬁbrinogen, intercellular adhesion molecule-1,
interleukin-6, urinary isoprostanes, monocyte-chemoattrac-
tant protein-1, and tumor necrosis receptor factor 2 (Table 5
and Figure 1). The maximal statistically signiﬁcant improve-
ment of the area under the curve was observed upon addition
of CRP (from 0.63 to 0.69, P value 0.002). However, once we
additionally accounted for the clinical variables, all associa-
tions were attenuated (all P>0.07, Table 5 and Figure 2). The
multivariable model containing clinical covariates showed an
area under the curve equal to 0.89. We were not able to
detect any improvement of the c statistic after addition of any
of the inﬂammatory biomarkers (from 0.886 to 0.892, all
P values >0.10 when compared to the clinical prediction
model).
Secondary Analyses
There were no interactions with sex (all P>0.02). The additional
analysis with sex-speciﬁc quartiles for CRP showed increased
odds of developing diabetes among those in the third and
Table 2. Biomarker Concentrations at Baseline According to
Diabetes Status at Follow-Up
Baseline (n=2638)
Diabetes (n=162) No Diabetes (n=2476)
CRP, mg/L 3.51 (1.49, 8.15) 1.84 (0.90, 4.39)
CD40 ligand, ng/mL 1.21 (0.55, 4.04) 1.26 (0.54, 4.03)
Fibrinogen, mg/dL 382 (338, 445) 366 (324, 413)
Intercellular adhesion
molecule-1, ng/mL
258 (223, 292) 236 (206, 273)
Interleukin-6, pg/mL 3.52 (2.27, 5.08) 2.38 (1.65, 3.74)
Urine isoprostanes,
ng/mmol
147 (104, 204) 126 (87, 186)
LpaPA2 mass,
nmol/mL per min
324 (268, 412) 302 (245, 371)
LpaPA2 activity, ng/mL 277 (216, 357) 282 (226, 352)
Monocyte
chemoattractant
protein-1, pg/mL
146 (122, 171) 138 (116, 163)
P-selectin, pg/mL 5.21 (4.50, 6.29) 5.15 (4.25, 6.13)
Osteoprotegerin, pmol/L 37 (30, 48) 35 (28, 44)
Tumor necrosis factor
receptor 2, pg/mL
2100 (1804, 2570) 1888 (1586, 2256)
Values are given as median (lower quartile, upper quartile). CRP indicates C-reactive
protein; LpaPA2, lipoprotein-associated phospholipase A2.
Table 3. Reasons for Participant Exclusion
Baseline Follow-Up
Examination Offspring 7 Omni 2 Offspring 8 Omni 3
Prevalent type 2
diabetes at
baseline
366 53 ……
Offsite baseline
examination
205 2 ……
Missing baseline
plasma glucose
level
36 9 ……
Missing baseline
type 2 diabetes
status,
biomarkers, and
clinical
covariates
17 2 ……
Failure to attend
subsequent
examination
…… 416 78
Missing glucose
data on follow-up
…… 19 2
Incomplete
diabetes status
on follow-up
…… 64 10
Totals 591 126 499 90
Table 4. Participant Clinical Characteristics of Those Meeting
Baseline Examination* Criteria by Status of Follow-Up
Examination Attendance
Attended Follow-Up Examination
†
Characteristics Yes No, Alive No, Deceased
Baseline examination*, n 2733 291 203
Omni cohort, % 7 24 4
Female, % 56 58 39
Age, y 59.4 59.8 69.1
Prevalent cardiovascular
disease, %
91 2 2 6
Glucose, mg/dL 96.6 96.9 99.5
*Offspring examination 7 or Omni examination 2.
†Offspring examination 8 or Omni examination 3.
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for age, sex, and cohort. These associations were attenuated
after addition of the clinical variables to model 1 (Table 6).
We performed a post hoc power calculation. At a
signiﬁcance level of 0.05, we had 80% power to detect an
association of type 2 diabetes with a biomarker, provided the
Figure 1. Least-squares adjusted means and standard errors for the different inﬂammatory biomarkers after adjustment for age, sex, and
cohort. CRP indicates C-reactive protein; CD40L, CD40 ligand; ICAM, intercellular adhesion molecule 1; IL-6, interleukin-6; Isopro, urinary
isoprostanes; MASS and ACTV, lipoprotein-associated phospholipase A2 mass and activity, respectively; MCP-1, monocyte chemoattractant
protein-1; OPG, osteoprotegerin; Psel, P-selectin; and TNFR2, tumor necrosis factor receptor 2.
Table 5. Odds Ratios for Type 2 Diabetes Related to Biomarkers and C Statistics for the Corresponding Models
Model 1: Age, Sex, Cohort Model 2: Multivariable*
Biomarkers
† OR (95% CI) PC Statistic P
‡ OR (95% CI) PC Statistic P
‡
Model without biomarkers 0.634 0.890
CRP 1.64 (1.39–1.94) <0.0001 0.692 0.002 1.17 (0.94–1.46) 0.16 0.891 0.34
CD40 1.02 (0.87–1.19) 0.85 0.633 0.43 1.06 (0.88–1.28) 0.51 0.891 0.29
Fibrinogen 1.24 (1.05–1.47) 0.011 0.648 0.20 0.91 (0.75–1.11) 0.35 0.890 0.68
ICAM 1.45 (1.24–1.70) <0.0001 0.676 0.002 1.18 (0.99–1.42) 0.07 0.891 0.13
IL-6 1.42 (1.23–1.65) <0.0001 0.677 0.003 1.07 (0.87–1.31) 0.55 0.890 0.38
Urine isoprostanes 1.33 (1.10–1.60) 0.003 0.641 0.044 1.16 (0.92–1.44) 0.21 0.886 0.22
LpaPA2 mass 0.95 (0.81–1.12) 0.55 0.633 0.79 0.92 (0.76–1.12) 0.41 0.890 0.73
LpaPA2 activity 1.17 (0.97–1.41) 0.10 0.638 0.51 1.14 (0.92–1.42) 0.24 0.892 0.14
MCP-1 1.23 (1.04–1.47) 0.018 0.644 0.35 1.17 (0.96–1.43) 0.13 0.891 0.11
P-selectin 1.11 (0.94–1.31) 0.23 0.637 0.43 0.89 (0.74–1.07) 0.21 0.891 0.71
Osteoprotegerin 1.09 (0.92–1.31) 0.32 0.637 0.30 0.98 (0.80–1.20) 0.86 0.890 0.71
TNFR2 1.36 (1.16–1.60) 0.0001 0.661 0.022 1.07 (0.88–1.30) 0.49 0.889 0.44
*Multivariable model: adjusted for age, sex, cohort, body mass index, fasting glucose, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, and smoking. Odds ratio
(95% conﬁdence interval) expressed as per standard deviation.
†CRP indicates C-reactive protein; CD40L, CD40 ligand; ICAM, intercellular adhesion molecule 1; IL-6, interleukin-6; LpaPA2, lipoprotein-associated phospholipase A2; MCP-1, monocyte
chemoattractant protein-1; OPG, osteoprotegerin; and TNFR2, tumor necrosis factor receptor-2.
‡P value for c statistic between model with biomarker and without biomarker.
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the log biomarker level.
Discussion
In our community-based sample, we observed an association
between new-onset type 2 diabetes and biomarkers associ-
ated with inﬂammation (CRP, ﬁbrinogen, interleukin-6, mono-
cyte-chemoattractant protein-1, and tumor necrosis receptor
factor 2), endothelial dysfunction (intercellular adhesion
molecule), and oxidative stress (urinary isoprostanes) after
adjustment for age, sex, and cohort. However, once we
accounted for easily obtainable clinical predictors of type 2
diabetes, these biomarkers were no longer independent
predictors of type 2 diabetes.
The experimental evidence suggesting a key role for
inﬂammation in the pathogenesis of diabetes is compelling.
Inﬂammation has been associated with insulin resistance
through the activation of receptors and transcription factors
that lead to b-cell dysfunction and apoptosis and impaired
insulin signaling.
22 The reduced sensitivity to insulin is
believed to protect the organism in the initial stage of an
inﬂammatory process, resulting in a better availability of
substrate for the immune system. However, the risk of new
onset of type 2 diabetes is increased by longstanding insulin
resistance.
23 In particular, obesity is considered one of the
most important risk factors for the development of insulin
resistance and type 2 diabetes. Macrophage cells recruited in
the fat tissue release large amounts of proinﬂammatory
cytokines, which result in an inhibitory effect on the insulin
signaling.
24
Figure 2. Least-squares adjusted means and standard errors for the different inﬂammatory biomarkers after adjustment for age, sex, cohort,
body mass index, fasting glucose, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, and smoking. CRP indicates
C-reactive protein; CD40L, CD40 ligand; ICAM, intercellular adhesion molecule 1; IL-6, interleukin-6; Isopro, urinary isoprostanes; MASS and
ACTV, lipoprotein-associated phospholipase A2 mass and activity, respectively; MCP-1, monocyte chemoattractant protein-1; OPG,
osteoprotegerin; Psel, P-selectin; and TNFR2, tumor necrosis factor receptor 2.
Table 6. Odds Ratios for Sex-Speciﬁc Quartiles for CRP in Relation to New-Onset of Type 2 Diabetes
Model 1 (Adjusted for Age, Sex, and Cohort) Model 2 (Multivariable Model*)
OR (95% CI) P OR (95% CI) P
Second quartile vs lowest quartile 1.04 (0.57–1.88) 0.90 0.68 (0.35–1.30) 0.24
Third quartile vs lowest quartile 2.12 (1.25–3.59) 0.0050 1.04 (0.57–1.88) 0.91
Fourth quartile vs lowest quartile 3.31 (2.01–5.47) <0.0001 1.21 (0.66–2.22) 0.54
*Multivariable model: adjusted for age, sex, cohort, body mass index, fasting glucose, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, and smoking.
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an association between CRP, ﬁbrinogen, interleukin-6, tumor
necrosis factor-a, tumor necrosis factor-a receptor 2, and
interleukin-18 and the new onset of diabetes.
10–20 However,
less has been reported about their ability to improve the
discriminatory power of models containing well-established
diabetes risk factors. Traditional statistical methods used for
the assessment of etiological associations might not be
adequate to determine the capacity of the marker of interest
for classifying or predicting risk for the individual.
25 In this
setting, Salomaa et al
17 identiﬁed in the FINRISK97 Cohort
the biomarkers apolipoprotein B100, CRP, interleukin-1
receptor antagonist, and ferritin as the strongest predictors
of incident diabetes. However, none of these biomarkers
was able to improve the c index or the integrated
discrimination improvement in the validation sample (Health
2000 cohort).
The Framingham type 2 diabetes clinical prediction model
developed in 2007 showed that easily obtainable clinical
characteristics could adequately predict type 2 diabetes, with
a c statistic of 0.89. Indeed, the primary risk factors for
developing type 2 diabetes were fasting glucose levels, the
presence of obesity (body mass index ≥30 kg/m
2), high-
density lipoprotein cholesterol levels, evidence for a positive
parental history, triglyceride levels ≥150 mg/dL, and elevated
blood pressure after adjustment for age and sex.
8 Evaluating
each of the inﬂammatory biomarkers in a model containing
only well-established clinical covariates, our results failed to
show an association between any of the biomarkers and the
new onset of type 2 diabetes but also did not provide an
improvement in the area under the curve of the baseline
model based on the clinical covariates. Given the lack of
association and the lack of a substantial change in the
c statistic, we do not have any strong indication that the
selected biomarkers could improve the ability to separate
individuals who will go on to develop diabetes from those who
will not.
26 Therefore, the calculation of the net reclassiﬁcation
improvement and the integrated discrimination improvement
were not warranted in this study.
Strengths and Limitations
The strengths of the present study include a community-
based sample, routine ascertainment of the outcome of
interest and potential confounders, and the availability of a
robust set of inﬂammatory markers, which were measured
serially with precise techniques to quantify their concentra-
tions. Some limitations warrant mention. Our sample
represents mostly non-Hispanic white individuals, and
therefore the generalizability of our ﬁndings to other ethnic
or racial minority groups is uncertain. Similarly, we did not
have sufﬁcient numbers of any one ethnic or racial group to
perform separate analyses. The results of our analysis were
based on single-occasion biomarker measurements, so day-
to-day variability of the biomarker itself could not be
assessed. New cases of type 2 diabetes were identiﬁed
through a single measurement of fasting glucose levels and
not through an oral glucose tolerance test as recommended
by the World Health Organization.
27 Whereas a challenge
test could be important pathophysiologically, oral glucose
tolerance tests are not used in everyday clinical practice
and are unlikely to be a major source of bias in our work.
Our analysis does not include parental history of diabetes,
which could contribute to a higher c statistic on the
baseline model. However, following the obtained results, one
would not expect an improvement of the area under the
curve of such a baseline model after addition of each
individual biomarker. In addition, we acknowledge some
selection and survival biases in our longitudinal assessment.
We had modest power to detect a small effect of the
association of interest. Whereas the modest power might
have affected our ability to detect small effects, it is unlikely
that such effects would lead to substantial improvement in
discrimination.
Systemic inﬂammation is associated with incident type 2
diabetes. We acknowledge that it is possible that inﬂamma-
tion contributes to the development of increasing blood
pressure and fasting glucose, which could be in the causal
pathway. However, none of the 12 inﬂammatory biomarkers
remained associated with incident type 2 diabetes after
standard clinical diabetes risk factors were accounted for,
and the addition of the inﬂammatory biomarkers did not
provide a signiﬁcant improvement in the area under the
curve. Our results reinforce the messages that easily
obtainable clinical predictors are sufﬁcient to identify indi-
viduals at risk for the development of diabetes and that
inﬂammatory biomarker assessments are unlikely to be
resource effective in further risk-stratiﬁcation of individuals
at risk of new-onset diabetes.
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